Mode and site of action of therapies targeting CGRP signaling

Abstract Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review focuses on summarizing the general pharmacology of the different types of treatment...

Full description

Bibliographic Details
Published in:	The Journal of Headache and Pain
Main Authors:	Alejandro Labastida-Ramírez, Edoardo Caronna, Cédric Gollion, Emily Stanyer, Austeja Dapkute, Diana Braniste, Hoda Naghshineh, Liga Meksa, Nino Chkhitunidze, Tamari Gudadze, Patricia Pozo-Rosich, Rami Burstein, Jan Hoffmann
Format:	Article
Language:	English
Published:	BMC 2023-09-01
Subjects:	Amylin Anti-CGRP Calcitonin Headache Migraine Trigeminal
Online Access:	https://doi.org/10.1186/s10194-023-01644-8

Similar Items

Sex differences in expression of CGRP family of receptors and ligands in the rat trigeminal system
by: Aida Maddahi, et al.
Published: (2024-11-01)

Differentially localizing isoforms of the migraine component calcitonin gene-related peptide (CGRP), in the mouse trigeminal ganglion: βCGRP is translated but, unlike αCGRP, not sorted into axons
by: Sofia Lyng Wæver, et al.
Published: (2025-01-01)

Future targets for migraine treatment beyond CGRP
by: Linda Al-Hassany, et al.
Published: (2023-06-01)

CGRP: New Focus in Migraine
by: Necdet Karlı, et al.
Published: (2022-03-01)

Peripherally acting anti-CGRP monoclonal antibodies alter cortical gray matter thickness in migraine patients: A prospective cohort study
by: Edina Szabo, et al.
Published: (2023-01-01)

Correlations between endogen amylin hormone and some hormonal, biochemical and bone parameters in pullets
by: S Guzel, et al.
Published: (2014-12-01)

Serum alpha-CGRP levels are increased in COVID-19 patients with headache indicating an activation of the trigeminal system
by: Gabriel Gárate, et al.
Published: (2023-03-01)

Characterization of erenumab and rimegepant on calcitonin gene-related peptide induced responses in Xenopus Laevis oocytes expressing the calcitonin gene-related peptide receptor and the amylin-1 receptor
by: Sanne Hage La Cour, et al.
Published: (2022-05-01)

Health Technology Assessment: Evaluation of 8 CGRP-Targeted Therapy Drugs for the Treatment of Migraine
by: Li M, et al.
Published: (2025-02-01)

The dual amylin and calcitonin receptor agonist KBP-336 elicits a unique combination of weight loss, antinociception and bone protection – a novel disease-modifying osteoarthritis drug
by: Khaled Elhady Mohamed, et al.
Published: (2024-07-01)

Chronic and intermittent administration of systemic nitroglycerin in the rat induces an increase in the gene expression of CGRP in central areas: potential contribution to pain processing
by: Rosaria Greco, et al.
Published: (2018-07-01)

Glycerol Trinitrate Acts Downstream of Calcitonin Gene-Related Peptide in Trigeminal Nociception—Evidence from Rodent Experiments with Anti-CGRP Antibody Fremanezumab
by: Nicola Benedicter, et al.
Published: (2024-03-01)

Effectiveness and Safety of CGRP-Targeted Therapies Combined with Lifestyle Modifications for Chronic Migraine in Korean Pediatric Patients: A Retrospective Study
by: Ji-Hoon Na, et al.
Published: (2025-05-01)

Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence—What Do We Know So Far?
by: Theodoros Mavridis, et al.
Published: (2021-07-01)

Advances in CGRP monoclonal antibodies as migraine therapy: A narrative review
by: Suruchi Aditya, et al.
Published: (2023-01-01)

Dynamic fluctuations of salivary CGRP levels during migraine attacks: association with clinical variables and phenotypic characterization
by: Alicia Alpuente, et al.
Published: (2024-04-01)

Amylin Receptor 1 Mutagenesis Revealed a Potential Role of Calcitonin Serine 29 in Receptor Interaction
by: Hyeseon Song, et al.
Published: (2025-07-01)

Development of High Affinity Calcitonin Analog Fragments Targeting Extracellular Domains of Calcitonin Family Receptors
by: Sangmin Lee
Published: (2021-09-01)

Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
by: Edoardo Caronna, et al.
Published: (2021-10-01)

Antinociceptive effects of dexmedetomidine via spinal substance P and CGRP
by: Li Ruiqin, et al.
Published: (2015-01-01)

CGRP-Targeting Therapies in Vestibular Migraine: A Synthesis of Observational Evidence with Direction-of-Effect Analysis
by: Alin Ciubotaru, et al.
Published: (2026-06-01)

The Anti-CGRP Antibody Fremanezumab Lowers CGRP Release from Rat Dura Mater and Meningeal Blood Flow
by: Mária Dux, et al.
Published: (2022-05-01)

CGRP Plasma Levels Correlate with the Clinical Evolution and Prognosis of Hospitalized Acute COVID-19 Patients
by: Manuela Rizzi, et al.
Published: (2022-09-01)

Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders
by: Sait Ashina, et al.
Published: (2023-03-01)

Use of rimegepant as an alternative to triptans in migraine treatment
by: Aleksandra Jaroń, et al.
Published: (2024-08-01)

Effect of CGRP inhibitors on interictal cerebral hemodynamics in individuals with migraine
by: Sarah C. Carter, et al.
Published: (2024-04-01)

Rodent behavior following a dural inflammation model with anti-CGRP migraine medication treatment
by: Philip V. Reducha, et al.
Published: (2023-02-01)

Neuropeptide FF receptor 2 inhibits capsaicin-induced CGRP Upregulation in mouse trigeminal ganglion
by: Ya-Tin Lin, et al.
Published: (2020-07-01)

The role of amylin, a gut–brain axis hormone, in metabolic and neurological disorders
by: Tahir Muhammad, et al.
Published: (2025-03-01)

Croatian guidelines for specific preventive treatment of migraine with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP) (eptinezumab, fremanezumab, and galcanezumab) or the CGRP receptor (erenumab)
by: Davor Jančuljak, et al.
Published: (2024-01-01)

Ex vivo stimulation of the trigeminal nucleus caudalis induces peripheral CGRP release in the trigeminal ganglion and reveals a distinct dopamine–endocannabinoid mechanism relevant to migraine
by: Isabella Mai Christiansen, et al.
Published: (2025-06-01)

Treatment of resistant chronic migraine with anti-CGRP monoclonal antibodies: a systematic review
by: Hugo Sevivas, et al.
Published: (2022-06-01)

Substance P release from rat dura mater is inversely correlated with CGRP release– experiments using glycerol trinitrate and anti-CGRP antibodies
by: Mária Dux, et al.
Published: (2025-05-01)

Real-world experience of galcanezumab in the prevention of migraine in Spain: a systematic literature review
by: Patricia Pozo-Rosich, et al.
Published: (2024-11-01)

The Role of Purinergic Mechanisms in the Excitability of Trigeminal Afferents of Rats with Prenatal Hyperhomocysteinemia
by: Elizaveta Ermakova, et al.
Published: (2025-03-01)

Xiongzhi Dilong decoction interferes with calcitonin gene-related peptide (CGRP)-induced migraine in rats through the CGRP/iNOS pathway
by: Qing Wang, et al.
Published: (2022-07-01)

Differential inhibitory response to telcagepant on αCGRP induced vasorelaxation and intracellular Ca2+ levels in the perfused and non-perfused isolated rat middle cerebral artery
by: André Erdling, et al.
Published: (2017-05-01)

AMYLIN AND AMYLIN ANALOGS – FUTURE THERAPEUTIC STRATEGIES FOR THE TREATMENT OF TYPE 2 DIABETES AND OBESITY
by: Nikolinka Koleva, et al.
Published: (2026-06-01)

Calcitonin gene-related peptide-targeting drugs and Raynaud’s phenomenon: a real-world potential safety signal from the WHO pharmacovigilance database
by: Alexandre O. Gérard, et al.
Published: (2022-05-01)

Influence of Constipation in the Behavior of Circulating Alpha- and Beta-CGRP Levels in Chronic/High-Frequency Migraine Patients After CGRP Monoclonal Antibodies
by: Gabriel Gárate, et al.
Published: (2025-05-01)